 |
|
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer
A Randomized Clinical Trial
Ian M. Thompson, Jr, MD;
Catherine M. Tangen, DrPH;
Jorge Paradelo, MD;
M. Scott Lucia, MD;
Gary Miller, MD, PhD ;
Dean Troyer, MD;
Edward Messing, MD;
Jeffrey Forman, MD;
Joseph Chin, MD;
Gregory Swanson, MD;
Edith Canby-Hagino, MD;
E. David Crawford, MD
JAMA. 2006;296:2329-2335.
Context Despite a stage-shift to earlier cancer stages and lower tumor volumes for prostate cancer, pathologically advanced disease is detected at radical prostatectomy in 38% to 52% of patients. However, the optimal management of these patients after radical prostatectomy is unknown.
Objective To determine whether adjuvant radiotherapy improves metastasis-free survival in patients with stage pT3 N0 M0 prostate cancer.
Design, Setting, and Patients Randomized, prospective, multi-institutional, US clinical trial with enrollment between August 15, 1988, and January 1, 1997 (with database frozen for statistical analysis on September 21, 2005). Patients were 425 men with pathologically advanced prostate cancer who had undergone radical prostatectomy.
Intervention Men were randomly assigned to receive 60 to 64 Gy of external beam radiotherapy delivered to the prostatic fossa (n = 214) or usual care plus observation (n = 211).
Main Outcome Measures Primary outcome was metastasis-free survival, defined as time to first occurrence of metastatic disease or death due to any cause. Secondary outcomes included prostate-specific antigen (PSA) relapse, recurrence-free survival, overall survival, freedom from hormonal therapy, and postoperative complications.
Results Among the 425 men, median follow-up was 10.6 years (interquartile range, 9.2-12.7 years). For metastasis-free survival, 76 (35.5%) of 214 men in the adjuvant radiotherapy group were diagnosed with metastatic disease or died (median metastasis-free estimate, 14.7 years), compared with 91 (43.1%) of 211 (median metastasis-free estimate, 13.2 years) of those in the observation group (hazard ratio [HR], 0.75; 95% CI, 0.55-1.02; P = .06). There were no significant between-group differences for overall survival (71 deaths, median survival of 14.7 years for radiotherapy vs 83 deaths, median survival of 13.8 years for observation; HR, 0.80; 95% CI, 0.58-1.09; P = .16). PSA relapse (median PSA relapse–free survival, 10.3 years for radiotherapy vs 3.1 years for observation; HR, 0.43; 95% CI, 0.31-0.58; P<.001) and disease recurrence (median recurrence-free survival, 13.8 years for radiotherapy vs 9.9 years for observation; HR, 0.62; 95% CI, 0.46-0.82; P = .001) were both significantly reduced with radiotherapy. Adverse effects were more common with radiotherapy vs observation (23.8% vs 11.9%), including rectal complications (3.3% vs 0%), urethral strictures (17.8% vs 9.5%), and total urinary incontinence (6.5% vs 2.8%).
Conclusions In men who had undergone radical prostatectomy for pathologically advanced prostate cancer, adjuvant radiotherapy resulted in significantly reduced risk of PSA relapse and disease recurrence, although the improvements in metastasis-free survival and overall survival were not statistically significant.
Trial Registration clinicaltrials.gov Identifier: NCT00394511
Author Affiliations: University of Texas Health Science Center at San Antonio (Drs Thompson, Troyer, Swanson, and Canby-Hagino); Southwest Oncology Group Statistical Center, Seattle, Wash (Dr Tangen); Kansas City Community Clinical Oncology Program, Kansas City, Mo (Dr Paradelo); University of Colorado Health Sciences Center, Denver (Drs Lucia, Miller, and Crawford); James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY (Dr Messing); Wayne State University School of Medicine, Detroit, Mich (Dr Forman); University of Western Ontario, Department of Surgical Oncology, London, Ontario (Dr Chin).
Deceased.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Advanced Prostate Cancer and Postoperative Radiotherapy
David L. Sherr
JAMA. 2007;297(9):950.
EXTRACT
| FULL TEXT
Advanced Prostate Cancer and Postoperative Radiotherapy
Thomas M. Pisansky, Alan Pollack, Howard M. Sandler, and Richard K. Valicenti
JAMA. 2007;297(9):950-951.
EXTRACT
| FULL TEXT
Advanced Prostate Cancer and Postoperative Radiotherapy—Reply
Ian M. Thompson and Catherine M. Tangen
JAMA. 2007;297(9):951.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era
Stephenson et al.
JCO 2009;27:4300-4305.
ABSTRACT
| FULL TEXT
Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95
Wiegel et al.
JCO 2009;27:2924-2930.
ABSTRACT
| FULL TEXT
Is There a Standard of Care for Pathologic Stage T3 Prostate Cancer?
Thompson et al.
JCO 2009;27:2898-2899.
FULL TEXT
Risk Stratification of High-grade Prostate Cancer Treated with Antegrade Radical Prostatectomy with Intended Wide Resection
Yamamoto et al.
Jpn J Clin Oncol 2009;39:387-393.
ABSTRACT
| FULL TEXT
Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial
Ray et al.
JNCI J Natl Cancer Inst 2009;101:228-236.
ABSTRACT
| FULL TEXT
Reply to the Letter to the Editor from Fromont
Shariat and Karakiewicz
Clin. Cancer Res. 2009;15:413-413.
FULL TEXT
Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy
Blum et al.
Clin. Cancer Res. 2008;14:7790-7797.
ABSTRACT
| FULL TEXT
Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy
Trock et al.
JAMA 2008;299:2760-2769.
ABSTRACT
| FULL TEXT
Resolving the Optimal Timing of Radiotherapy After Radical Prostatectomy: The Need for Further Research
Parker and Sydes
JCO 2008;26:e3-e3.
FULL TEXT
External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy
Shariat et al.
JCO 2008;26:1526-1531.
ABSTRACT
| FULL TEXT
Prognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Hashimoto et al.
Jpn J Clin Oncol 2008;0:hym135v1-5.
ABSTRACT
| FULL TEXT
Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy
Moinpour et al.
JCO 2008;26:112-120.
ABSTRACT
| FULL TEXT
Adjuvant Radiotherapy After Surgery for Pathologically Advanced Prostate Cancer
Van der Kwast et al.
JCO 2007;25:5671-5672.
FULL TEXT
"No Turning Bax" in the Combined Battle against Prostate Cancer:
Rajendran and Kao
Clin. Cancer Res. 2007;13:3435-3438.
FULL TEXT
Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794
Swanson et al.
JCO 2007;25:2225-2229.
ABSTRACT
| FULL TEXT
The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients
Jani et al.
Clin Med Res 2007;5:123-131.
ABSTRACT
| FULL TEXT
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson et al.
JCO 2007;25:2035-2041.
ABSTRACT
| FULL TEXT
Advances in the Treatment of Localized Prostate Cancer: The Role of Anatomic and Functional Imaging in Men Managed With Radiotherapy
Speight and Roach
JCO 2007;25:987-995.
ABSTRACT
| FULL TEXT
Advanced Prostate Cancer and Postoperative Radiotherapy
Sherr
JAMA 2007;297:950-950.
FULL TEXT
Advanced Prostate Cancer and Postoperative Radiotherapy
Pisansky et al.
JAMA 2007;297:950-951.
FULL TEXT
Improving Men's Health: Evidence and Opportunity.
Fontanarosa and Cole
JAMA 2006;296:2373-2375.
FULL TEXT
Adjuvant Radiotherapy for High-Risk Patients with Prostate Cancer
JWatch Oncology and Hematology 2006;2006:2-2.
FULL TEXT
|
